Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Intracranial Meningioma Clinical Trial

Official title:
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Status Terminated

Clinical Trial Summary

In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00972335
Study type	Interventional
Source	SCRI Development Innovations, LLC
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2010
Completion date	July 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03180268` - Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery	Phase 3
Recruiting	`NCT02523014` - Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	Phase 2
Active, not recruiting	`NCT02974127` - Multisession Radiosurgery in Large Meningiomas
Not yet recruiting	`NCT05832099` - Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints
Not yet recruiting	`NCT02084927` - Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery	Phase 1